openPR Logo
Press release

The Startup Funding Matchmaker Behind $160 in Deals - Why Spectup Is the Name Founders (and VCs) Are Whispering

05-23-2025 09:32 PM CET | Politics, Law & Society

Press release from: ABNewswire

The Startup Funding Matchmaker Behind $160 in Deals - Why Spectup

While startup headlines are often dominated by moonshot valuations and flashy funding rounds, there's a consultancy quietly turning raw potential into real money - and doing it with ruthless precision.

Meet Spectup [https://spectup.com/] led by ex-Deloitte and BMW Startup Garage alum Niclas Schlopsna, Spectup is the go-to fundraising consultancy for growth-stage startups and the VCs hunting for the next big thing. But don't mistake them for your average pitch deck polishers - Spectup isn't in the business of fluff. They're in the business of funding.

Fundraising Without the Fluff

With over $500 million in investments facilitated and a client list that spans over 100 high-growth companies - from SaaS giants to AI disruptors - Spectup's playbook is simple: get founders investor-ready, fast. That means real financial modeling, real investor outreach, and real connections to capital that actually converts.

As Schlopsna puts it:

"Startups don't need more theory. They need traction, funding, and exits. We bring the shortest path to all three."

Spectup handles everything from Series A to D fundraising prep - including pitch decks that get opened, numbers that hold up in diligence, and intros to investors who aren't just browsing. Their success stories include preparing platforms like CreatorIQ to their $40 million Series D and advising AI and biotech ventures raising seven- to eight-figure rounds globally.

The Investor's Secret Weapon

But here's where Spectup flips the script: they're not just helping startups. They're a hidden edge for institutional investors, too.

Private equity firms, VCs, and family offices tap Spectup for:

*
Off-market deal origination

*
LP fundraising for new venture funds

*
Venture scout programs and diligence support

It's a rare dual-side model - startups trust Spectup to get them funded, and investors trust Spectup to find vetted, high-quality opportunities. That inside edge comes straight from Schlopsna's hybrid background: part operator, part strategist, part scout. Few others can claim that vantage point - and make it work at scale.

Sourcing Smarter, Growing Faster

Spectup's network reaches beyond Europe, quietly vetting over 50+ startups annually across verticals like HealthTech, Blockchain, GreenTech, FinTech, and AI. Each opportunity is handpicked, pressure-tested, and aligned with investors' actual mandates - not just hype.

"Our bar is high," Schlopsna says. "We only bring in startups we'd invest in ourselves. Otherwise, what's the point?"

It's an approach that's paying off. Spectup's curated deals now serve a growing global network of investors hungry for substance over flash - and they're just getting started.

For Founders and Funds Ready to Move

In an ecosystem flooded with noise, Spectup is a signal booster. Whether you're a startup prepping for a raise, or a VC looking for deals worth your time, they make one thing clear:

Mediocre doesn't cut it.

Learn more or book a call with Spectup founder Niclas Schlopsna at spectup.com [https://www.spectup.com/]

Media Contact
Company Name: Spectup
Contact Person: Niclas Schlopsna
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-startup-funding-matchmaker-behind-160-in-deals-why-spectup-is-the-name-founders-and-vcs-are-whispering]
Country: United States
Website: http://spectup.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Startup Funding Matchmaker Behind $160 in Deals - Why Spectup Is the Name Founders (and VCs) Are Whispering here

News-ID: 4034090 • Views:

More Releases from ABNewswire

Glioblastoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharma
Glioblastoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Trea …
DelveInsight's, "Glioblastoma- Pipeline Insight, 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Glioblastoma treatment pipeline includes over 180 key companies actively
Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc
Alzheimer's Disease Clinical Trials, Companies, Therapeutic Assessment, Therapie …
DelveInsight's, "Alzheimer's disease- Pipeline Insight, 2025" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Alzheimer's Disease treatment pipeline includes over 110
Acute Lymphocytic Leukemia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Orca Biosystems, Inc., Jazz Pharmaceuticals, Shenzhen TargetRx
Acute Lymphocytic Leukemia Clinical Trials, Companies, Therapeutic Assessment, T …
DelveInsight's, "Acute Lymphocytic Leukemia (ALL) - Pipeline Insight, 2025," report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Acute Lymphocytic Leukemia (ALL) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. According to DelveInsight, the Acute Lymphocytic
Iron Deficiency Anemia Market Poised for Robust Growth Through 2034, Driven by Rising Prevalence, Novel Therapies, and Advancing Clinical Pipelines | DelveInsight
Iron Deficiency Anemia Market Poised for Robust Growth Through 2034, Driven by R …
The iron deficiency anemia treatment market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Akebia, Shield Therapeutics, AMAG Pharmaceuticals, Nemysis, Pharmacosmos Therapeutics, CSL Vifor, American Regent, JW Pharmaceutical, and Zeria Pharmaceutical, among others. DelveInsight's "Iron Deficiency Anemia Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the iron deficiency anemia treatment market, historical and

All 5 Releases